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3-Hydroxy-3-methylglutaryl–Coenzyme A Reductase Inhibitors
(Statins) Induce Hepatic Expression of the Phospholipid
Translocase mdr2 in Rats
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PETER L. M. JANSEN,‡ FOLKERT KUIPERS,¶ and MICHAEL MU¨LLER‡
Groningen Institute for Drug Studies, ‡Division of Gastroenterology and Hepatology, *Department of Pharmacokinetics and Drug Delivery,
00Department of Pathology, and ¶Department of Pediatrics, University of Groningen, Groningen, The Netherlands; and §Department of Pathology,
Free University Hospital, Amsterdam, The Netherlands
Background & Aims: Biliary cholesterol secretion is
coupled to that of phospholipids in a process con-
trolled by mdr2 P-glycoprotein activity and bile salt
secretion. Statins, the 3-hydroxy-3-methylglutaryl–
coenzyme A (HMG-CoA) reductase inhibitors, have
been shown to affect hepatobiliary lipid secretion in
rats. The aim of this study was to relate the effects of
statins on bile formation to the expression of mdr2 and
other hepatic adenosine triphosphate–dependent trans-
port proteins involved in bile formation in rats. Methods:
Rats received simvastatin- or pravastatin-containing
chow continuously for 5 days. In one group of rats,
simvastatin treatment was withdrawn 9–12 hours be-
fore the end of the experiment to induce biliary choles-
terol hypersecretion (rebound). Bile and liver tissue
were collected for lipid analysis, and hepatic messen-
ger RNA (mRNA) and protein levels were studied by
reverse-transcription polymerase chain reaction, immu-
noblotting, and immunohistochemistry. Results: Simva-
statin feeding did not alter biliary bile salt secretion.
Secretion of phospholipids and cholesterol was stimu-
lated by 74% and 90%, respectively, in the simvastatin-
continuous group and by 72% and 235%, respectively,
in the rebound group compared with controls. mdr2
mRNA levels increased only in the continuous group.
mdr2 protein levels increased in both simvastatin-fed
groups. Induction was most pronounced in periportal
hepatocytes. mdr1b mRNA levels were moderately
increased in both simvastatin-fed groups. Levels of
other hepatic transport proteins did not change. Simi-
lar results were obtained in pravastatin-fed rats.
Conclusions: Statins increase expression of mdr2 and
mdr1b in rats, revealing a novel effect of these com-
monly used drugs.
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl–coenzyme A (HMG-CoA) reductase,
a key enzyme in cholesterol biosynthesis.1 These drugs
are widely used in the treatment of hypercholesterolemic
patients.2 Statins lower plasma low-density lipoprotein
(LDL) cholesterol levels in humans by (1) enhanced
clearance of LDL by transcriptional up-regulation of
hepatic LDL receptors and/or (2) reduced production of
LDL by either decreasing its secretion into the plasma or
by decreasing the conversion of very-low-density lipopro-
tein to LDL.3,4 Statins do not lower plasma cholesterol
levels in rodents that carry most of their plasma choles-
terol in the high-density lipoprotein fraction.5 Yet statins
have been shown to affect hepatobiliary lipid secretion in
rats. Long-term (.5 days) statin treatment results in
induction of hepatic HMG-CoA reductase expression and
enzyme levels and promotes biliary lipid output.6,7
Additionally, cessation of statin treatment leads to marked
hypersecretion of cholesterol into bile within 6–12
hours,8,9 accompanied by a relatively smaller increase in
biliary phospholipid secretion.9 Bile salt secretion, on the
other hand, is not influenced.6,8,9 Because both choles-
terol and phospholipid secretion are coupled to that of
bile salts,10 the statin-induced secretion of lipids indi-
cates that these drugs exert specific actions in the liver.
The hypersecretion of cholesterol into bile after statin
withdrawal has been attributed to an inappropriately
high hepatic cholesterol synthesis because of induction of
the HMG-CoA reductase system.8 Evidently, this does
not explain the concomitant hypersecretion of phospho-
lipids.
Abbreviations used in this paper: ABC, adenosine triphosphate–
binding cassette; HMG-CoA, 3-hydroxy-3-methylglutaryl–coenzyme
A; LDL, low-density lipoprotein; MDR, multidrug resistance; MRP,
multidrug-resistance protein; mdr, mrp, genes encoding multidrug-
resistance proteins; PC, pravastatin-continuous; PCR, polymerase
chain reaction; Pgp, P-glycoprotein; SC, simvastatin-continuous;
spgp, sister of Pgp; SR, simvastatin-rebound; SRE, sterol regulatory
element; SREBP, sterol regulatory element–binding protein.
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Recently, it has become clear that phospholipid secre-
tion into bile is controlled by mdr2 P-glycoprotein (Pgp)
in the bile canalicular membrane.11 This mdr2-Pgp is a
member of the Pgp subfamily of adenosine triphosphate–
binding cassette (ABC) transport proteins, which in
rodents comprises at least 4 members that are all localized
in the canalicular domain of hepatocytes: mdr1a, mdr1b,
mdr2, and spgp. Expression of mdr2 in normal rodent
liver is high, and evidence indicates that this protein
functions as a flippase that translocates phosphatidylcho-
line across the membrane.11 In contrast to mdr2, mdr1a
and mdr1b are present at low levels in normal rat liver.12
Overexpression of the latter 2 proteins in cells confers
multidrug resistance against a broad variety of natural
product drugs.13,14 The physiological function of mdr1a
and mdr1b in the liver presumably involves hepatobiliary
transport of bulky amphiphilic compounds, including
hydrophobic peptides, steroids, and, perhaps, certain
lipids.14–16 Spgp, the product of the so-called sister gene
of Pgp, is abundantly present in rat canalicular mem-
branes and was recently shown to function as the major
bile salt export pump.17,18
The multidrug-resistance protein (MRP1) and its
isoforms are members of another subfamily (MRP/CFTR)
of the ABC protein superfamily.15,19 The human MRP1
and its rat homologue mrp1 are expressed at low levels in
the normal liver.20,21 The recently cloned mrp1 homo-
logue mrp222,23 has a similar substrate specificity as mrp1
and is highly expressed in the canalicular membrane
domain of hepatocytes and functions as a canalicular
multispecific organic anion transporter.24,25 Mrp2 has
been implicated in the removal of pravastatin from the
body by mediating its secretion into bile.26
To gain insight in the mechanism(s) underlying statin-
associated changes in biliary lipid secretion, we have
evaluated the effects of continuous and discontinuous
administration of simvastatin on the expression of genes
encoding hepatic ABC transport proteins. For compari-
son, rats were continuously exposed to pravastatin or to




Pathogen-free male Wistar rats (270–310 g) were
purchased from Harlan (Zeist, Netherlands). They were housed
at the Central Animal Facility of the University of Groningen
in a temperature-controlled environment with alternating
12-hour light (6 AM to 6 PM) and dark cycles. All experiments
were performed between 7 and 9 AM. The rats received standard
laboratory chow (RMH-B; Hope Farms BV, Woerden, Nether-
lands) and had free access to food and water. The study was
approved by the local committee for care and use of laboratory
animals.
Experimental Design
Three independent animal experiments were per-
formed.
Experiment A. Rats were fed for 5 days with either the
standard control diet (control, n 5 10) or the same diet
supplemented with 0.1% (wt/wt) simvastatin (Merck, Sharp &
Dome, Whitehouse Station, NJ). At the end of the 5-day
period, one of the simvastatin-supplemented groups was
returned to the control diet 9–11 hours before the end of the
experiment (simvastatin-rebound; SR group, n 5 10) and the
other group was maintained on simvastatin-supplemented diet
(simvastatin-continuous; SC group, n 5 10). On the morning
of day 6, rats were anesthetized with pentobarbital (60 mg/kg
intraperitoneally). Of each group, 3 animals were subjected to
bile duct catheterization to allow collection of bile.29 After a
5-minute stabilization period, bile was collected for 30 min-
utes and stored at –20°C for further analysis. The livers were
perfused with phosphate-buffered saline (PBS), excised, weighed,
cut into small pieces, snap-frozen in liquid nitrogen, and stored
at –80°C until use for isolation of membranes or of RNA. For
immunohistochemistry study, small pieces of liver were frozen
in isopentane and stored at –80°C until further use. Blood
samples were collected in EDTA-containing tubes and centri-
fuged immediately (10,000g), and plasma was stored at –20°C
until used.
Experiment B. Experiment A was repeated as de-
scribed, except that simvastatin was replaced by pravastatin
(Bristol–Myers Squibb, Princeton, NJ), and that a ‘‘rebound’’
group was omitted. Rats were fed for 5 days with either the
control diet (control, n 5 3) or the same diet supplemented
with 0.1% (wt/wt) pravastatin (pravastatin-continuous; PC
group, n 5 5). At the end of the 5 days, bile was sampled, the
rats were killed, and tissue was collected as described for the
rats in the experiment with simvastatin.
Experiment C. Rats were fed for 5 days with either the
standard control diet (control, n 5 3) or the same diet
supplemented with 0.5% (wt/wt) diosgenin, a plant saponin
(Sigma Chemical Co., St. Louis, MO) (diosgenin, n 5 3). At
the end of the 5 days, bile was sampled, the rats were killed,
and tissue was collected as described for the rats in experiment
A with simvastatin.
Antibodies
Mouse monoclonal antibody C219 (Signet Laborato-
ries, Dedham, MA) was used for detection of all Pgps. This
antibody recognizes a conserved epitope close to the ABC in all
known members of the Pgp subfamily.30,31 Polyclonal antibod-
ies against mdr2 (k111) were raised by immunizing rabbits
with the peptide EEFEVELSDEKA coupled to keyhole limpet
hemocyanin (KLH) via the NH2-terminus.32 k111 was used for
the detection of mdr2 on immunoblots. Mouse monoclonal
antibody P3II-26, raised against a specific sequence of the
human MDR333 (kindly provided by Dr. R. J. Scheper, Free
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University Hospital, Amsterdam, Netherlands), was used for
immunohistochemical detection of rat mdr2 Pgp. On Western
blot, k111 and P3II-26 recognize a 170-kilodalton protein in
canalicular membrane–enriched fractions from rat liver but not
in basolateral membrane–enriched fractions. In addition, in
membrane subfractions from insect cells infected with a
recombinant baculovirus expressing the rat mdr2 gene, a single
band was observed, whereas no specific signals were detected in
membranes from cells overexpressing the rat mdr1b, human
MDR1, or human MRP1 genes (data not shown). Polyclonal
antibodies against spgp (k12) and mrp2 (k4) were raised in our
laboratory.21
mRNA Analysis by Reverse-Transcription
PCR
Total RNA was isolated from frozen rat liver using
TRIzol Reagent (GIBCO BRL, Grand Island, NY) according
to the manufacturer’s instructions. Subsequently, mRNA was
isolated using the Oligotex mRNA Mini-kit (Qiagen GmbH,
Hilden, Germany). Single-stranded complementary DNA
(cDNA) was synthesized from 2.5 µg mRNA and subsequently
subjected to relative polymerase chain reactions (PCRs) as
described by our laboratory.21 Specific primer sets for the
various hepatic ABC proteins were designed; for each primer
set, an increasing number of PCR cycles with otherwise fixed
conditions was performed to determine the optimal number of
cycles to be used. This was determined to be halfway through
the exponential phase. For every PCR reaction, glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was used as the internal
control. The number of cycles was 22 for GAPDH and mrp2,
24 for spgp, 29 for mdr1b and mdr2, and 33 for mdr1a and
mrp1. The primer sequences and product sizes have been
described previously.21 Sequence analysis confirmed the speci-
ficity of the PCR primers for each PCR product. In each
experiment, water was used as a negative control. Ten microli-
ters of PCR product was loaded on a 2.5% agarose gel and
stained with ethidium bromide. Images were taken using a
charge-coupled device video camera of the ImageMaster VDS
system (Pharmacia, Uppsala, Sweden).
Isolation of Membranes From Liver
Homogenates
Crude liver cell membrane fractions and canalicular
membrane–enriched fractions were isolated by the sucrose
gradient centrifugation techniques described by Meier and
Boyer,34 with some modifications as detailed by Vos et al.21 For
later use, membrane fractions were stored at –80°C in 10
mmol/L Tris-HCl (pH 7.4) with Complete protease inhibitor
cocktail (1:50, wt/vol; Boehringer Mannheim GmbH, Mann-
heim, Germany).
Western Blot Analysis
The crude cell membrane proteins (100 µg) or canalicu-
lar membrane–enriched proteins (15 µg) were separated on
7.5% sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis and transferred to nitrocellulose (Amersham International,
Buckinghamshire, England), using a tankblotting system
according to the manufacturer’s instructions (Bio-Rad Labora-
tories, Hercules, CA). BDH molecular weight standards
(42,700–200,000-dalton range, BDH Ltd., Dorset, England)
were used as marker proteins. The blots were stained with
Ponceau S solution (0.1% Ponceau S [wt/vol] in 5% acetic acid
[vol/vol]; Sigma) to confirm similar protein concentrations in
every lane. The blots were incubated with the first antibody
diluted in PBS containing 4% nonfat dried milk powder (Fluka
BioChemica, Buchs, Switzerland) and 0.05% polyoxyethylene
sorbitan monolaurate (Tween 20; Sigma); washed in PBS/
0.05% Tween 20; incubated with horseradish peroxidase–
labeled swine anti-rabbit immunoglobulin (Ig) G or rabbit
anti-mouse IgG (dilution 1:2000; Dako A/S, Glostrup, Den-
mark); and finally developed using Pierce SuperSignal Chemi-
luminescent Substrate Luminol/Enhancer (Pierce, Rockford,
IL).
Immunohistology
For immunohistological studies, 4-µm sections were
cut from frozen liver tissue. After drying, the sections were
fixed in acetone for 10 minutes at room temperature. The
monoclonal antibodies C219 and P3II-26 and the polyclonal
antibody k12 were diluted (1:50, 1:250, and 1:50, respectively)
in PBS containing 1% bovine serum albumin. Sections were
incubated with 50 µL of the diluted antibody for 60 minutes.
After incubation with the first antibody, endogenous peroxi-
dase activity was blocked by incubating the sections in 50 mL
PBS containing 125 µL of a 30% H2O2 solution for 30 minutes
at room temperature. Slides incubated with the monoclonal
antibodies C219 and P3II-26 were subsequently incubated
with peroxidase-conjugated rabbit anti-mouse IgG (dilution,
1:50) for 30 minutes followed by incubation with peroxidase-
conjugated goat anti-rabbit IgG (dilution, 1:50) for another 30
minutes. Slides incubated with the polyclonal antibody k12
were subsequently incubated with peroxidase-conjugated goat
anti-rabbit IgG (dilution, 1:100) for 30 minutes followed by
incubation with peroxidase-conjugated rabbit anti-goat IgG
(dilution 1:100) for another 30 minutes. All peroxidase-
conjugated immunoglobulins were diluted in PBS containing
1% bovine serum albumin and 5% normal rat serum. Peroxi-
dase activity was developed with 3-amino-9-ethylcarbazole
solution (0.2 mg/mL sodium acetate buffer containing 0.03%
H2O2) for 15 minutes at room temperature. Nuclear counter-
staining was performed with hematoxylin, and the slides were
covered with Kaiser’s glycerin-gelatin. All antibody incuba-
tions were performed at room temperature; after each incuba-
tion, sections were rinsed with PBS.
Analytical Procedures
Protein concentrations were determined with the DC
Protein Assay (Bio-Rad) using bovine serum albumin as
standard. Bile salt concentrations were determined by an
enzymatic fluorometric assay (Sterognost-Flu; Nyegaard & Co.,
Oslo, Norway). Levels of triglycerides, cholesterol, cholesteryl
ester, and phospholipids were measured in liver homogenates
or bile after lipid extraction, according to Bligh and Dyer35 and
as described by Kuipers et al.29 Plasma cholesterol and
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triglyceride levels were measured using a commercially avail-
able kit (Boehringer Mannheim). Alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) activities and total
bilirubin concentrations in plasma were determined by routine
clinical chemistry.
Statistical Analysis
All data are expressed as mean values 6 SEM. Statisti-
cal analysis between the experimental groups was performed
using one-way analysis of variance (ANOVA), followed by the
Student–Newman–Keuls test (simvastatin experiment), or
using the unpaired Student t test (pravastatin and diosgenin
experiments). Level of significance for all statistical analysis




We observed no significant differences in body
weights or liver/body weight ratios between the control
and simvastatin-treated groups (simvastatin-rebound [SR]
and simvastatin-continuous [SC]; data not shown). Dur-
ing simvastatin treatment, bile flow was slightly in-
creased from 6.8 6 0.9 µL · min21 · 100 g body wt21 in
the control group to 8.1 6 1.0 and 9.0 6 1.8 µL · min21 ·
100 g body wt21 in the SR and SC groups, respectively,
but this did not reach statistical significance. This
modest increase may be the result of biliary secretion of
simvastatin and/or its metabolites.36 No differences were
found in either plasma ALT and AST activities or total
bilirubin concentrations between the 3 experimental
groups (data not shown).
Effects of Simvastatin on Plasma, Hepatic,
and Biliary Lipids
Various parameters of lipid metabolism in control
and simvastatin-treated rats are compared in Table 1.
Plasma cholesterol concentrations were not affected in SR
and SC rats, but plasma triglyceride levels were signifi-
cantly reduced to 40% and 37%, respectively, of control
values. Continuous administration of simvastatin had no
effect on the amounts of free cholesterol and cholesteryl
ester in the liver. Withdrawal of simvastatin resulted in a
significant increase of hepatic cholesteryl ester content to
280% of control values. Hepatic phospholipid and
triglyceride levels were not significantly different among
the 3 experimental groups. Simvastatin administration
had no significant effects on biliary bile salt output.
However, a profound effect on the biliary output rates of
phospholipids and cholesterol was observed: simvastatin
increased the phospholipid content of bile to 174% of
control values in the SC group and to 172% in the SR
group when expressed relative to bile salt content (Figure
1). Biliary cholesterol/bile salt ratios increased to 190%
and 335% of control values in the SC and SR groups,
respectively, whereas the cholesterol/phospholipid ratio
was significantly increased in the SR group only, to 185%
of control values (see Figure 1).
Effects of Simvastatin on mRNA Levels of
ABC Transport Proteins in Liver
The relative mRNA levels of selected hepatic
ABC transport proteins were analyzed by reverse-
transcription PCR. We preferred reverse-transcription
PCR analysis over Northern blotting because the latter
technique is not sensitive enough to detect mdr1a, mdr1b,
and mrp1 transcripts in the normal rat liver. Also, the
specificity of the PCR reactions can be confirmed by
sequencing the PCR products. Administration of simva-
statin did not result in major changes of mdr1a, spgp,
mrp1, and mrp2 mRNA levels (Figure 2). In contrast,
mdr2 mRNA levels in the SC group were strongly
induced but were unaltered in the SR group. mdr1b
mRNA levels were increased in the SC and, to a lesser
extent, in SR groups.
Effects of Simvastatin on Protein Levels of
ABC Transporters in Liver
Expression levels of various hepatic ABC transport
proteins were examined by Western blot analysis of crude
liver membranes and canalicular membrane–enriched
fractions. The results of experiment A are shown in
Figure 3. All liver samples from the various experimental
groups were tested in this way, and similar results were
Table 1. Plasma and Hepatic Lipid Levels and Biliary Output




Cholesterol 1.45 6 0.12 1.52 6 0.11 1.59 6 0.18
Triglycerides 0.98 6 0.11 0.40 6 0.13a 0.36 6 0.12a
Liver (nmol/mg protein)
Total cholesterol 33.9 6 2.43 45.9 6 4.05a,b 34.7 6 2.36
Free cholesterol 29.7 6 1.64 37.1 6 2.90 31.3 6 1.80
Cholesteryl ester 3.32 6 0.73 9.29 6 1.18a,b 2.97 6 0.62
Triglycerides 38.9 6 5.40 34.2 6 7.49 30.3 6 3.48
Phospholipids 231 6 7.2 235 6 6.4 255 6 6.9
Biliary output
(nmol · min21 · 100
g body wt21)
Bile salts 200 6 30 227 6 11 265 6 29
Cholesterol 5.7 6 0.63 21.5 6 3.12a,b 14.3 6 1.91a
Phospholipids 27.7 6 5.9 53.3 6 6.5a 62.9 6 5.8a
NOTE. Plasma and liver values represent the average 6 SEM of 10
animals. Biliary output rates represent the average 6 SEM of 3
animals.
aSignificantly different from controls (P , 0.01).
bSignificantly different from continuous (P , 0.01).
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obtained (n 5 10 for each group). Continuous simva-
statin administration resulted in pronounced increase of
the C219 signal (detecting all Pgps) both in crude
membrane pellets (Figure 3) and in canalicular membrane–
enriched fractions (data not shown). Pgp levels remained
elevated in the SR group. Mdr2 was increased in both SC
and SR groups (Figure 3). Spgp protein levels remained
unchanged. A slight decrease of mrp2 protein was
observed in the SC group. Levels of dipeptidylpeptidase
IV (dppIV) protein, used as a canalicular marker protein,
were similar in all membrane fractions (data not shown).
Localization of ABC Transporters in Livers
of Simvastatin-Treated Rats
Immunohistochemical analysis of liver sections
was performed to assess whether the simvastatin-induced
expression of mdr1b and mdr2 resulted in changes in the
distribution pattern of the encoded Pgps in liver. In
control liver, the intensities of P3II-26 (detecting mdr2)
and of C219 (detecting all Pgps) signals were stronger in
periportal than perivenous regions, although staining of
P3II-26 was weak (Figure 4A and C). Pgps were exclu-
sively found in the canalicular domain of hepatocytes.
After simvastatin treatment, however, the P3II-26 signal
was strongly increased, predominantly in periportal areas
of the liver lobule (Figure 4B), whereas the induced C219
signal was more homogeneously distributed in treated rat
liver (Figure 4D). No differences were observed between
SC and SR groups (data not shown). In control liver,
spgp, as detected by k12, was uniformly disposed across
the liver acinus; this disposition was not affected by
simvastatin administration (Figure 4E and F).
Effects of Pravastatin and Diosgenin on
Bile Formation and mdr Expression
To study the specificity of the observed induction
of mdr2 and mdr1b by simvastatin, experiments were
performed with rats that received the hydrophilic HMG-
CoA reductase inhibitor pravastatin according to the
continuous protocol (pravastatin-continuous [PC]). In
addition, another established model of biliary cholesterol
hypersecretion, the diosgenin-fed rat, was included in the
study. Pravastatin or diosgenin administration did not
have significant effects on any of the animal characteris-Figure 1. Relative bile salt, phospholipid, and cholesterol contents in
bile of control rats and simvastatin-treated rats. Rats were fed
standard chow (control; h), simvastatin-containing chow that was
replaced 9–11 hours before the end of the experiment (j), or
simvastatin-containing chow continuously (N). Bile was collected for
30 minutes as described in Materials and Methods. Data are
presented as ratios 3 103 of data presented in Table 1 and represent
the average 6 SEM of 3 animals. BS, bile salts; CH, cholesterol; PL,
phospholipids. *P , 0.01, significantly different from control; ‡P ,
0.01, significantly different from SC.
Figure 2. Mdr1a, mdr1b, mdr2, spgp, mrp1, and mrp2 mRNA expres-
sion during simvastatin treatment. Lanes 1 and 2, control (Con); lanes
3 and 4, simvastatin-rebound (SR); lanes 5 and 6, simvastatin-
continuous (SC). mRNA was isolated from control rat liver or simva-
statin-treated rat liver, and 2.5 µg mRNA was transcribed into cDNA
and subjected to PCR analysis as described in Materials and Methods.
Each band represents the results of a single animal. PCR products are
indicated at the left side of each gel, corresponding base pairs at the
right side, and the experimental group above the figure. Representa-
tive experiment of 5–7/group.
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tics described before. However, during pravastatin treat-
ment, bile flow increased significantly from 7.1 6 0.6
µL · min21 · 100 g body wt21 in the control group to
10.0 6 0.7 µL · min21 · 100 g body wt21 in the PC
group, most likely because of biliary excretion of pravas-
tatin.26,37 Diosgenin feeding did not have an effect on bile
flow. Plasma lipid levels and biliary lipid output rates of
control and pravastatin-treated animals are shown in
Table 2. Plasma lipid levels were not significantly
affected in the PC group compared with controls. Biliary
output rates of bile salts as well as lipids were increased in
the PC group compared with controls. However, when
expressed relative to bile salt content, the biliary phospho-
lipid and cholesterol contents in the PC group were not
significantly increased (Figure 5), although both phospho-
lipid and cholesterol output rates were clearly increased
in treated animals (Table 2). In rats treated with dios-
genin, biliary cholesterol output was stimulated about
6-fold, whereas phospholipid and bile salt secretion were
not affected, as reflected in the marked increases in
cholesterol/bile salt and cholesterol/phospholipid ratios
(Figure 6). Relative reverse-transcription PCR analysis of
cDNA prepared from PC livers revealed an increase in
mdr2 and mdr1b mRNA levels (Figure 7), albeit less
evidently as observed in SC livers (Figure 2). Diosgenin
treatment had no effect on mRNA levels of any of the
tested proteins (data not shown).
Discussion
This study shows that statins increase the expres-
sion of mdr2 and mdr1b in rat liver. For an effect on mdr2
expression, a continuous exposure to statins appeared to
be necessary, because mdr2 mRNA levels returned to
control levels within 9–12 hours after simvastatin with-
drawal. However, during this rebound phase, mdr2
protein levels remained elevated and, accordingly, biliary
phospholipid secretion was increased in both SC and SR
groups. In contrast, mdr1b mRNA levels remained
increased in the SR group, indicating different mecha-
nisms of induction of mdr2 and mdr1b gene expression or
differences in mRNA stability.
Statin treatment did not affect plasma cholesterol
levels in rats, but simvastatin drastically reduced plasma
triglycerides, as expected.5 The effect on plasma triglycer-
ides was sustained after withdrawal of simvastatin,
probably indicating that hepatic very-low-density lipopro-
tein production remained suppressed during the time
course of this experiment. Neither liver size nor hepatic
lipid content was affected by continuous statin feeding.
In the simvastatin-rebound group, hepatic cholesterol
and cholesteryl ester contents were strongly elevated,
probably the result of an inappropriately high synthesis of
cholesterol.8 It is known that competitive inhibitors of
HMG-CoA reductase strongly induce synthesis of HMG-
CoA reductase while inhibiting its activity.8,38,39
Simvastatin administration did not affect spgp expres-
sion and did not alter biliary bile salt output in either SC
or SR groups. We observed a 2-fold increase in phospho-
lipid output in simvastatin-treated animals concomitant
with the increase in mdr2 protein levels. These data
clearly support the important role of mdr2 in the
regulation of biliary phospholipid secretion, as initially
deduced from studies using mice with a disrupted mdr2
gene.40 Accordingly, biliary phospholipid secretion com-
pared with that of bile salts is increased in mice in which
hepatic mdr2 expression is induced by fibrate feeding41
and in mice overexpressing MDR3, the human homo-
logue of mdr2.42 The finding that biliary cholesterol/
phospholipid ratios in SC and control groups are identi-
cal, despite suppression of cholesterol synthesis in the
first group, suggests that phospholipid secretion per se is
an important regulatory factor of cholesterol secretion.
On the other hand, in the SR group cholesterol secretion
is markedly enhanced relative to both bile salts and
phospholipids. This indicates that, in this condition with
Figure 3. Pgps, spgp, mrp2, and mdr2 protein levels in membrane
fractions of control rat liver and simvastatin-treated rat liver. Lanes 1
and 2, control (Con); lanes 3 and 4, simvastatin-rebound (SR); lanes 5
and 6, simvastatin-continuous (SC). Livers from control rats and
simvastatin-treated rats were used for the isolation of crude plasma
membranes or canalicular membrane–enriched fractions; 100 µg of
crude membrane proteins or 15 µg of canalicular membrane–enriched
proteins was subjected to sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and transferred to a nitrocellulose filter. Immunoblot-
ting analysis was performed using the primary antibodies C219, k12,
k4, and k111, recognizing all Pgps, mrp2, spgp, or mdr2, respectively.
Bound antibodies were visualized as described in Materials and
Methods. For the analysis of Pgps, spgp, and mrp2, crude membrane
protein fractions were used. Mdr2 could only be detected in canalicu-
lar membrane protein-enriched fractions. Each band represents the
results of a single animal. Transport proteins are indicated at the left
side of each blot, apparent molecular weights at the right side, and
experimental group above the blot. Representative experiment of
5–7/group.
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an abrupt increase in de novo synthesis of cholesterol, the
availability of excess cholesterol in the liver acts as an
independent regulator of biliary cholesterol secretion.
To determine the specificity of the observed induction
of mdr2 and mdr1b mRNA, the effects of pravastatin
administration on expression of these genes was also
studied. In addition, a group of rats was fed diosgenin,
representing another model of biliary cholesterol hyperse-
cretion. In contrast to simvastatin, pravastatin treatment
did not affect plasma triglycerides, indicating that, at the
dosage used, simvastatin is a more potent inhibitor of
sterol synthesis than pravastatin.43,44 As a result, no
profound changes in biliary lipid secretion compared
with that of bile salts were observed, although there is a
tendency toward stimulated biliary lipid secretion in PC
animals. Also, a clear increase in mdr2 and mdr1b mRNA
levels was detected in pravastatin-treated rats, suggesting
similar cellular actions of simvastatin and pravastatin
that are mediated via shared pathways. Data from
diosgenin-treated rats demonstrate that hypersecretion of
cholesterol can occur independently of mdr2 induction
and that cholesterol hypersecretion per se does not cause
induction of mdr2.
In conclusion, our data suggest that the induction of
mdr2 expression, and, consequently, of biliary phospho-
lipid secretion in statin-treated rats gives rise to a
proportional increase in cholesterol secretion. Cessation
of statin treatment results in an additional stimulation of
biliary cholesterol secretion that may be related to rapid
expansion of the intracellular cholesterol pool because of a
sudden increase in cholesterol synthesis.
Statins cause a transient state of cellular free cholesterol
deprivation, resulting in enhanced transcription of sterol-
regulated genes,45 mediated by sterol regulatory element–
Figure 4. Immunohistochemi-
cal localization of (A and B)
mdr2, (C and D) C219, and (E
and F ) spgp in (A, C, and E)
control rat liver and (B, D, and
F ) simvastatin-treated rat liver.
Frozen liver sections were
stained with primary antibodies
directed against mdr2, all Pgps,
and spgp using P3II-26, C219,
and k12, respectively. In nor-
mal rat liver, (A) staining of
mdr2, although weak, was
slightly stronger in periportal
regions, (C) as was the staining
of C219. (E ) In normal rat liver,
spgp protein was uniformly dis-
tributed across the liver acinus.
(B) In treated liver, mdr2 stain-
ing was predominantly in-
creased in periportal areas. (D)
C219 staining of treated rat
liver revealed a homogeneous
staining throughout the liver lob-
ule, which was increased com-
pared with control rat liver. (F )
In treated rat liver, spgp stain-
ing was not affected compared
with control rat liver. c, central
area; p, portal area. Typical
staining patterns of 4–6/group
(original magnification 203).
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binding proteins (SREBPs).46 SREBPs activate transcrip-
tion by binding to sterol regulatory elements (SREs) in
the promoter regions of target genes.46 Importantly,
SREBP-1 is down-regulated and SREBP-2 is up-
regulated in livers of hamsters and mice during treatment
with lovastatin and a bile salt–binding resin.47,48 We
hypothesize that transcriptional control of mdr2 gene
expression might, at least partially, be mediated via
SREBPs. The 58-flanking region of the mdr2 gene49
contains elements that are possibly recognized by SREBPs:
an inverted motif that is homologous to SRE-350 (posi-
tion 2278 to 2269) and an inverted SRE-1 half-site
(position 2193 to 2188).51
The mdr2-positive cells were mainly localized to
periportal regions of control livers; this was also true in
livers from simvastatin-treated animals. This zonal distri-
bution is very similar to the reported distribution of
HMG-CoA reductase and HMG-CoA synthase before
and after statin treatment,38,52 which suggests that the
factors controlling the expression of mdr2 and these
enzymes may be similar. Staining with C219 of control
rat liver revealed a similar heterogeneous staining pattern
as observed for P3II-26. However, unlike P3II-26, the
C219 signal was more homogeneously distributed in
simvastatin-treated animals. Because the spgp staining is
unchanged and the mdr2 staining is predominantly
increased in periportal regions after simvastatin treat-
ment, we conclude that this may, at least partially, be the
result of increased expression of mdr1b Pgp.
Figure 5. Relative bile salt, phospholipid, and cholesterol contents in
bile of control rats and pravastatin-treated rats. Rats were fed
standard chow (h) or pravastatin-containing chow (j). Bile was
collected for 30 minutes as described in Materials and Methods. Data
are presented as ratios 3 103 and represent the average 6 SEM of 3
control and 5 pravastatin-treated animals. BS, bile salts; CH, choles-
terol; PL, phospholipids.
Figure 6. Relative bile salt, phospholipid, and cholesterol contents in
bile of control rats and diosgenin-treated rats. Rats were fed standard
chow (h) or diosgenin-containing chow (j). Bile was collected for 30
minutes as described in Materials and Methods. Data are presented
as ratios 3 103 and represent the average 6 SEM of 3 animals. Note
the axis break. BS, bile salts; CH, cholesterol; PL, phospholipids.
*P , 0.001, significantly different from control.
Figure 7. Mdr1b and mdr2 mRNA expression during pravastatin
treatment. Lanes 1–3, control (Con); lanes 4–6, pravastatin-
continuous (PC). mRNA was isolated from control rat liver or pravastatin-
treated rat liver; 2.5 µg mRNA was transcribed into cDNA and
subjected to PCR analysis as described in Materials and Methods.
Each band represents the results of a single animal. PCR products are
indicated at the left side of each gel, corresponding base pairs at the
right side, and experimental group above the figure. Representative
experiment of 3–5/group.





Cholesterol 1.95 6 0.07 1.78 6 0.12
Triglycerides 0.51 6 0.06 0.46 6 0.05
Biliary output (nmol · min21 · 100 g
body wt21)
Bile salts 256 6 32 361 6 39
Cholesterol 4.6 6 0.49 7.9 6 0.87a
Phospholipids 37.7 6 3.0 62.7 6 6.5a
NOTE. Plasma values represent the average 6 SEM of 3 control and 5
pravastatin-treated animals. Biliary output rates represent the aver-
age 6 SEM.
aSignificantly different from controls (P , 0.05).
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Mdr1b mRNA levels also respond to statin administra-
tion, although this response is not as dramatic as observed
in other experimental conditions.53–55 The induction of
mdr1b mRNA persists after cessation of simvastatin
treatment, in contrast to the situation observed for mdr2.
This may be the result of a longer half-life of mdr1b
mRNA, enhanced transcription rate, or a differential
regulation of the expression of these 2 genes,12,53,54 which
is in accordance with the different physiological functions
of these proteins. In rat liver, a direct induction of mdr1b
gene expression has been shown as a result of exposure to
various xenobiotics,12,56,57 but the mechanism by which
mdr1b mRNA is induced remains to be determined.
Yamazaki et al.26 recently provided evidence that the
biliary excretion of the relatively hydrophilic statin
pravastatin is predominantly mediated by mrp2. Whether
mrp2 is also involved in the biliary excretion of simva-
statin or its metabolites is not known. Because of their
hydrophobic nature, mdr1a/1b may also be candidate
transport proteins.
In conclusion, we have shown that during treatment of
rats with the HMG-CoA reductase inhibitors simvastatin
and pravastatin, the expression of mdr2 and of mdr1b is
enhanced, revealing a novel, until now unrecognized
effect of these cholesterol-lowering agents. Increased
mdr2 expression may facilitate removal of excess choles-
terol that enters the liver as a consequence of induced
LDL receptor activity during statin treatment. In addi-
tion, these findings may provide clues for mechanisms
involved in regulation of Pgp expression and function in
rat liver.
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